[go: up one dir, main page]

AR057623A1 - Materiales y metodos para el tratamiento de las infecciones virales - Google Patents

Materiales y metodos para el tratamiento de las infecciones virales

Info

Publication number
AR057623A1
AR057623A1 ARP060105117A ARP060105117A AR057623A1 AR 057623 A1 AR057623 A1 AR 057623A1 AR P060105117 A ARP060105117 A AR P060105117A AR P060105117 A ARP060105117 A AR P060105117A AR 057623 A1 AR057623 A1 AR 057623A1
Authority
AR
Argentina
Prior art keywords
treatment
influenza
materials
methods
viral infections
Prior art date
Application number
ARP060105117A
Other languages
English (en)
Original Assignee
Omega Bio Pharma H K Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omega Bio Pharma H K Ltd filed Critical Omega Bio Pharma H K Ltd
Publication of AR057623A1 publication Critical patent/AR057623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Materiales y métodos para el tratamiento de diversos trastornos de salud, incluyendo la prevencion y/o tratamiento de una infeccion viral. En una realizacion preferida, se administra un compuesto de cisteamina a un sujeto para tratar una infeccion por el virus de la influenza. Más preferentemente, se administra un compuesto de cisteamina a un sujeto para tratar infecciones por los virus influenza A, influenza B, influenza C, incluyendo los subtipos de virus influenza aviar (tales como el virus influenza aviar H5N1).
ARP060105117A 2005-11-28 2006-11-22 Materiales y metodos para el tratamiento de las infecciones virales AR057623A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74058405P 2005-11-28 2005-11-28
US81077306P 2006-06-02 2006-06-02
US81888506P 2006-07-06 2006-07-06
US84702006P 2006-09-25 2006-09-25

Publications (1)

Publication Number Publication Date
AR057623A1 true AR057623A1 (es) 2007-12-05

Family

ID=37769370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105117A AR057623A1 (es) 2005-11-28 2006-11-22 Materiales y metodos para el tratamiento de las infecciones virales

Country Status (21)

Country Link
US (2) US8415398B2 (es)
EP (1) EP1954258B8 (es)
JP (1) JP5138603B2 (es)
KR (1) KR101440629B1 (es)
CN (1) CN102038667A (es)
AP (1) AP2877A (es)
AR (1) AR057623A1 (es)
AU (1) AU2006318355B2 (es)
BR (1) BRPI0619377A2 (es)
CA (1) CA2631241C (es)
DK (1) DK1954258T3 (es)
ES (1) ES2392976T3 (es)
HK (1) HK1123726A1 (es)
IL (1) IL191705A (es)
MX (1) MX2008006851A (es)
MY (1) MY141003A (es)
NZ (1) NZ568464A (es)
PL (1) PL1954258T3 (es)
PT (1) PT1954258E (es)
TW (1) TWI401079B (es)
WO (1) WO2007062272A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528090A (en) * 2004-01-13 2005-09-01 Omega Bio Pharma I P 2 Ltd Methods for treating stress and affecting biological immune systems
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US8026284B2 (en) 2006-01-27 2011-09-27 The Regents Of The University Of California Enterically coated cystamine, cysteamine and derivatives thereof
JP2010528053A (ja) * 2007-05-25 2010-08-19 オメガ バイオ−ファルマ （エイチ．ケイ．） リミテッド インフルエンザ感染症を治療するための物質および方法
US20120058937A9 (en) * 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
US20120308608A1 (en) * 2010-02-01 2012-12-06 Megan Shaw Interferon-inducing compounds and uses thereof
ES2647223T3 (es) * 2010-04-15 2017-12-20 Biota Scientific Management Pty Ltd Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
EP3778603A1 (en) 2013-09-12 2021-02-17 Janssen BioPharma, Inc. 7,8-dihydro-3h-pyrazino[1,2-b]pyridazine-3,5(6h)-dione compounds and uses thereof
AU2016229147C1 (en) 2015-03-11 2021-03-25 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
JP2020501503A (ja) 2016-12-15 2020-01-23 ソシエテ・デ・プロデュイ・ネスレ・エス・アー コンパニオンアニマルにおけるリン又は酵素を調節する組成物及び方法
US11612576B2 (en) 2017-09-20 2023-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
CN115884764A (zh) * 2020-04-01 2023-03-31 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
CN115605193A (zh) * 2020-05-13 2023-01-13 密歇根大学董事会（Us） 用于治疗SARS-CoV-2感染的半胱胺
IL298267A (en) * 2020-05-25 2023-01-01 Novabiotics Ltd Antiviral treatment
WO2022040045A1 (en) * 2020-08-18 2022-02-24 New Amsterdam Sciences, Inc. Sod mimetic and methods of using same for the treatment of covid-19
CN118871100A (zh) * 2021-12-07 2024-10-29 西拉治疗公司 抗病毒治疗剂及其用途
WO2024009307A1 (en) * 2022-07-06 2024-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Viroporins blockers/inhibitors as anti-flaviviruses agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3538160A (en) 1965-03-24 1970-11-03 Smithkline Corp Pentacyclooctaneamines
US3483254A (en) 1967-01-03 1969-12-09 Merck & Co Inc 2-bornanemethylamines
US3496228A (en) 1967-02-16 1970-02-17 Smithkline Corp Aminotricyclononanes and the salts thereof
US3534084A (en) 1968-10-16 1970-10-13 Squibb & Sons Inc Adamantylamino-naphthyloxypropanols and related compounds
US3592934A (en) 1969-06-20 1971-07-13 Du Pont Pharmaceutical compositions and methods of controlling influenza a virus infection utilizing substituted adamantanes and tricyclo(4.3.1.13.8) undecanes
IT1055560B (it) 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2027527A6 (es) 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros dotados de actividad antiviral.
DE4103177A1 (de) 1991-02-02 1992-08-06 Boehringer Mannheim Gmbh Thiazolo-(2,3-a)isoindol-derivate und diese enthaltende arzneimittel
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5725870A (en) 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
CA2173964A1 (en) * 1993-10-15 1995-04-20 Jess G. Thoene Prevention of hiv infection
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5684024A (en) 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
CA2326771A1 (en) * 1998-03-30 1999-10-07 Endowment For Research In Human Biology, Inc. (The) Agents and methods for modulation of zinc transfer by metallothionein
DE19817511A1 (de) * 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.
US6063383A (en) 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
CN1537009A (zh) 2001-04-25 2004-10-13 �ư������������޹�˾ 一种用于治疗或者预防个体功能性维生素b12缺陷的方法以及在该方法中使用的药物组合物
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US20060211748A1 (en) 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003900064A0 (en) 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US20040191295A1 (en) 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Also Published As

Publication number Publication date
AP2008004511A0 (en) 2008-06-30
AU2006318355A1 (en) 2007-05-31
NZ568464A (en) 2010-09-30
MX2008006851A (es) 2008-10-09
JP2009517395A (ja) 2009-04-30
TWI401079B (zh) 2013-07-11
HK1123726A1 (en) 2009-06-26
DK1954258T3 (da) 2012-10-15
US8415398B2 (en) 2013-04-09
CN102038667A (zh) 2011-05-04
EP1954258A1 (en) 2008-08-13
US20130338113A1 (en) 2013-12-19
TW200733953A (en) 2007-09-16
WO2007062272A1 (en) 2007-05-31
IL191705A (en) 2013-11-28
AU2006318355B2 (en) 2012-01-12
US20070135525A1 (en) 2007-06-14
AP2877A (en) 2014-03-31
PL1954258T3 (pl) 2013-01-31
PT1954258E (pt) 2012-10-22
EP1954258B1 (en) 2012-09-05
BRPI0619377A2 (pt) 2011-09-27
US9283198B2 (en) 2016-03-15
CA2631241C (en) 2014-02-11
CA2631241A1 (en) 2007-05-31
EP1954258B8 (en) 2012-10-10
IL191705A0 (en) 2009-02-11
KR20080077658A (ko) 2008-08-25
KR101440629B1 (ko) 2014-09-15
ES2392976T3 (es) 2012-12-17
MY141003A (en) 2010-02-12
JP5138603B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
AR057623A1 (es) Materiales y metodos para el tratamiento de las infecciones virales
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
MX346264B (es) Compuestos antivirales.
MX2020002151A (es) Compuestos antivirales.
ECSP17064986A (es) Compuestos antivirales
CL2015000870A1 (es) Análogos de 2&#39; -cloro nucleósido para infección por vhc.
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
EA201490588A1 (ru) Способы лечения вируса гепатита с
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
ECSP14013315A (es) Inhibidores de aplicación viral
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
EA201590197A1 (ru) Соединения для лечения парамиксовирусных вирусных инфекций
EA201491548A1 (ru) 2&#39;-замещенные карбануклеозидные аналоги для противовирусного лечения
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
SV2005001919A (es) Compuestos nucleosidos para el tratamiento de infecciones virales
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
WO2009023356A3 (en) Materials and methods for treating influenza infections
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
SV2007002309A (es) Compuestos 5-nitro-nucleosidos para tratar infecciones virales

Legal Events

Date Code Title Description
FB Suspension of granting procedure